In recent decades, monoclonal antibodies have become the most successful class of biotech drugs in the fields of hematology, oncology, autoimmune diseases, and infections. Besides the traditional IgG, IgA might be a great alternative since it recruits different effector cells. Based on years of experience, now Creative Biolabs provides professional IgA production and purification services for our universal customers.
Our Service
Delivering high-quality IgA antibody production and purification services, our platform ensures tailored solutions for both research and clinical applications. With expertise in producing both monomeric and dimeric IgA, the workflow begins with gene synthesis and plasmid construction upon receiving the sequence. Utilizing advanced expression system platforms, including Chinese hamster ovary (CHO) cells, myeloma cells, and baby hamster kidney cells, the process allows scalable production with optimized stability and efficacy. Hybridoma technologies with transgenic mouse models further ensure the reliable generation of monoclonal IgA antibodies, supporting both experimental and therapeutic needs.
Purification strategies are carefully selected to meet specific project goals. Offering specialized options such as lectin chromatography, affinity chromatography with protein A/G/L or peptide M, and ion exchange chromatography, our platform achieves high-affinity purification, particularly with peptide M technology. This method ensures superior selectivity and purity, tailored for precise downstream applications.
Fig.1 Schematic diagram of IgA structures—monomeric, dimeric, and secretory IgA.1
Service Process
Native IgA antibody development process
Animal immunization
Selection of antigen-specific igA+ memory B cells
Antibody expression and validation
Antibody sequencing
Recombinant antibody expression and purification
Antibody IgA transformation process
Animal immunization
Selection of antigen-specific IgG+ memory B cells
Antibody expression and validation
Antibody sequencing
IgA transformation and functional validation
Recombinant antibody expression and purification
Recombinant IgA antibody production process
Antibody variable region sequence
Selection IgA subtype of interest (IgA1, IgA2, IgA monomer, or IgA dimer)
Expression vector construction
Antibody expression and purification
Antibody QC and functional validation
Highlights
-
Comprehensive IgA Production & Purification Services
Providing end-to-end IgA antibody production and purification solutions tailored for both research and clinical applications, ensuring high-quality and project-specific outcomes. -
Cutting-edge Expression Systems for Optimal Yield
Leveraging advanced expression platforms, including CHO, myeloma, and baby hamster kidney cells, to achieve scalable production while maintaining stability and efficacy across batches. -
Customized Purification Strategies for Enhanced Specificity
Offering a selection of purification methods, such as lectin chromatography, affinity chromatography with protein A/G/L or peptide M, and ion exchange chromatography, all aligned with project-specific goals for high-quality output. -
Dual Technology Route
Offering dual pathways for successful projects, combining native IgA antibody development with specialized IgA transformation technology. -
Comprehensive Antibody Engineering Options
Extensive engineering strategies, including non-IgG antibody chimerization, antibody isotype switching, and non-IgG antibody humanization, provide flexible solutions to meet diverse project needs.
Background
In humans, IgA presents the most abundant antibody class at mucosal surfaces and the second most prevalent antibody in serum. Human serum contains mostly monomeric IgA and constitutes 15-20% of the whole immunoglobulins, while IgA exists in a dimeric and secretory form at mucosal surfaces. Similar to the IgG antibody, the IgA monomer contains two heavy chains and two light chains (κ or λ), which together form the constant and variable regions of IgA. IgA antibody acts as the first line of humoral immune at mucosal surfaces with two subclasses IgA1 and IgA2. The ratio of IgA1:IgA2 is approximately 9:1 in human serum. IgA1 is the predominant isotype in plasma that contains a 13 amino acid hinge region that enables it to have a more extended reach.
Despite the fact that IgG is the classical isoform for all available cancer therapies, IgA presents great advantages as a therapeutic agent. Firstly, monomeric IgA is more effective than IgG for the recruitment of polymorphonuclear neutrophils, which are the most abundant effector cell populations in humans for antibody-dependent cellular cytotoxicity against tumor cells. Secondly, the dimeric IgA enhances its signaling capacity on tumor cells and allows transportation into mucosal secretions, resulting in the targeting improvement in certain tumors.
FAQs
Q1: What expertise does Creative Biolabs offer in IgA antibody production?
A: Creative Biolabs specializes in IgA antibody production, offering end-to-end services that include gene synthesis, plasmid construction, and expression in advanced systems such as CHO, myeloma, and baby hamster kidney cells. With capabilities in both monomeric and dimeric IgA production, the platform supports scalable, stable, and effective antibody generation.
Q2: What makes the purification process at Creative Biolabs unique?
A: The purification process is highly tailored, with methods selected based on specific project needs. Options include lectin chromatography, protein A/G/L or peptide M affinity chromatography, and ion exchange chromatography. Peptide M technology is particularly effective in achieving superior selectivity and high purity, crucial for sensitive downstream applications.
Q3: What types of antibody engineering services are available for IgA?
A: Creative Biolabs provides comprehensive antibody engineering services, including chimerization, isotype switching, and humanization for IgA antibodies. These strategies allow flexible adaptation to research or therapeutic needs, facilitating projects that require specific structural or functional modifications.
Q4: How does Creative Biolabs ensure high-quality IgA antibody production?
A: The production process at Creative Biolabs is supported by a dual technology route, combining native IgA development with specialized IgA transformation. This approach, along with the use of cutting-edge expression systems and robust purification methods, guarantees high-quality and reliable IgA antibodies tailored for each project.
Resource
A Brief Introduction to Non-IgG Antibody - Creative Biolabs 
A Brief Introduction to Non-IgG Antibody - Creative Biolabs
Creative Biolabs is your best choice in terms of IgA antibody production and purification owing to decades of antibody development experience and all-around technology platforms. Our seasoned scientists can customize the most suitable products and services according to the specific requirements of customers. Please feel free to contact us or send us an inquiry if you are interested in non-IgG therapeutic antibodies.
Reference
- de Sousa-Pereira, Patrícia, and Jenny M. Woof. "IgA: structure, function, and developability." Antibodies 8.4 (2019): 57. Distributed under Open Access license CC BY 4.0, without modification.
KINDLY NOTE
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.
